Ignite Creation Date:
2025-12-25 @ 2:47 AM
Ignite Modification Date:
2026-01-01 @ 5:02 AM
Study NCT ID:
NCT04726033
Status:
COMPLETED
Last Update Posted:
2024-05-01
First Post:
2020-10-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
Sponsor:
Telix Pharmaceuticals (Innovations) Pty Limited
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-04
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-01-29
Completion Date Type:
ACTUAL
First Submit Date:
2020-10-14
First Submit QC Date:
None
Study First Post Date:
2021-01-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-29
Last Update Post Date:
2024-05-01
Last Update Post Date Type:
ACTUAL